Related Experiment Video
Updated: Nov 16, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Novel targeted therapies for Parkinson's disease
Theodora Ntetsika1,2, Paraskevi-Evita Papathoma1,3, Ioanna Markaki4,5
1Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Abstract:
Parkinson's disease (PD) is the second more common neurodegenerative disease with increasing incidence worldwide associated to the population ageing. Despite increasing awareness and significant research advancements, treatment options comprise dopamine repleting, symptomatic therapies that have significantly increased quality of life and life expectancy, but no therapies that halt or reverse disease progression, which remain a great, unmet goal in PD research. Large biomarker development programs are undertaken to identify disease signatures that will improve patient selection and outcome measures in clinical trials. In this review, we summarize PD-related mechanisms that can serve as targets of therapeutic interventions aiming to slow or modify disease progression, as well as previous and ongoing clinical trials in each field, and discuss future perspectives.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Targeted Cancer Therapies
There are several types of targeted therapies against...
Alzheimer's Disease: Treatment
Drug Therapy
Antianxiety Medications
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

